A07: Myeloid antigen plasticity as critical determinant of AML immune surveillance

Project A07 will explore regulatory networks shaping the immunopeptidome produced by AML blasts and analyzes the respective TCR responses. This project relies on the recently completed TEAM trial which examined the combination of Bortezomib as proteasome inhibitor with cytarabin and the anti-CD33 antibody Gemtuzumab-Ozogamicin. Proteasome inhibition might alter the AML intrinsic immunopeptidome and thus increase potential TCR targets.